Hypertrophic cardiomyopathy in workers who work in harmful working conditions: aspects of professional aptitude testing

Hypertrophic cardiomyopathy (HCM) is a myocardial disease associated with the risk of sudden cardiac death (SCD). The scientists examined the criteria for diagnosis and anatomical and morphological types, phenocopies of HCM, algorithms for examination and risk stratification of SCD, necessary when addressing issues of professional suitability based on clinical recommendations and regulations (Order of the Ministry of Health of the Russian Federation No. 29n). The clinical observation of a patient with HCM who was sent for a mandatory periodic medical examination is presented. The analysis showed that, according to Order No. 29n, the diagnosis of HCM in itself does not serve as a medical contraindication to work. A restriction of admission occurs if an employee has complications of the disease (life-threatening cardiac arrhythmias, chronic heart failure of functional class III–IV). At the same time, with an asymptomatic, non-obstructive variant of HCM, it is important to assess the risk of SCD according to special risk scales. Access to work with harmful working conditions is possible with a low risk of SCD. Thus, an individual assessment of professional aptitude, based on a comprehensive analysis of the patient's condition, SCD risk stratification data and compliance with industry standards, makes it possible to ensure occupational safety without unreasonable restrictions.

Contributions:
Gorokhova S.G. — concept and design of the study, data processing, writing;
Alpaev D.V. — data collection and processing, writing;
Korchagin I.A. — data collection and processing;
Strizhakov L.A. — design and editing;
Atkov O.Yu. — concept and editing.

Funding. The study had no funding.

Conflict of interest. The authors declare no conflict of interest.

Received: 10.09.2025 / Accepted: 06.10.2025 / Published: 30.10.2025

1. Shepel R.N., Samorodskaya I.V., Kakorina E.P., Drapkina O.M. Dynamics and structure of mortality from chronic coronary artery disease among men and women in the Russian Federation in 2014-2023. Rossijskij kardiologicheskij zhurnal. 2024; 29(12S): 6198. https://doi.org/10.15829/1560-4071-2024-6198 https://elibrary.ru/gkpesm (in Russian).

2. Aluru J.S., Barsouk A., Saginala K., Rawla P., Barsouk A. Valvular Heart Disease Epidemiology. Med. Sci. (Basel). 2022; 10(2): 32. https://doi.org/10.3390/medsci10020032

3. Ciarambino T., Menna G., Sansone G., Giordano M. Cardiomyopathies: An Overview. Int. J. Mol. Sci. 2021; 22(14): 7722. https://doi.org/10.3390/ijms22147722

4. Bai Y., Zheng J.P., Lu F., Zhang X.L., Sun C.P. et al. Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China. Sci. Rep. 2022; 12(1): 18799. https://pubmed.ncbi.nlm.nih.gov/36335106/

5. Clinical practice guidelines for Hypertrophic cardiomyopathy. 2025. https://clck.ru/3Pmk2n6 (in Russian).

6. Canepa M., Fumagalli C., Tini G., Vincent-Tompkins J., Day S.M. et al; SHaRe Investigators. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the international sarcomeric human cardiomyopathy registry. Circ. Heart Fail. 2020; 13: e007230. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007230

7. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Develop ment in (Young) Adults. Circulation. 1995; 92(4): 785–789. https://doi.org/10.1161/01.cir.92.4.785

8. Guo L., Gao C., Yang W., Ma Z., Zhou M., Liu J., et al. Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features. Front. Cardiovasc. Med. 2022; 9: 889523. https://doi.org/10.3389/fcvm.2022.889523

9. Katayama M. et al. Left ventricular septal hypertrophy in elderly patients with aortic stenosis. J. Ultrasound Med. 2017; 37(1): 217–224. https://doi.org/10.1002/jum.14320

10. Rodrigues J.C.L. et al. Prevalence and Predictors of Asymmetric Hypertensive Heart Disease: Insights from Cardiac and Aortic Function with Cardiovascular Magnetic Resonance. Eur. Hear. J. Cardiovasc. Imaging. 2016; 17(12): 1405–1413. https://doi.org/10.1093/ehjci/jev329

11. Belenkie I., MacDonald R.P.R., Smith E.R. Localized septal hypertrophy: Part of the spectrum of hypertrophic cardiomyopathy or an incidental echocardiographic finding? Am. Heart J. 1988; 115(2): 385–390. https://doi.org/10.1016/0002-8703(88)90486-3

12. Gardin J. et al. Localized basal ventricular septal hypertrophy — prevalence, functional and clinical correlates in a population referred for echocardiography. Am. J. Noninvas. Card. 1998; 6(1): 5–8.

13. Nde F., Nebo J., Ngatchou W., Tchatchoua C., Sone A.M., De Brouwer C. Impact of heavy load activity on cardiovascular system: echocardiographic assessment of informal construction workers heart in Cameroon. Pan. Afr. Med. J. 2014; 17: 79. https://doi.org/10.11604/pamj.2014.17.79.3674

14. Korshøj M., Skaarup K.G., Lassen M.C.H., Johansen N.D., Marott J.L., Schnohr P. et al. Association between exposure to heavy occupational lifting and cardiac structure and function: a cross-sectional analysis from the Copenhagen City Heart Study. Int. J. Cardiovasc. Imaging. 2022; 38: 521–532. https://doi.org/10.1007/s10554-021-02420-y

15. Korshøj M., Møller A., Siersma V., Lund R., Hougaard C.Ø., Mortensen O.S., Allesøe K. Relationship between cumulative exposure to occupational lifting throughout working life and risk of ischemic heart disease in men and women. The Copenhagen Aging and Midlife Biobank. Ann. Work Expo Health. 2024; 68(2): 109–121. https://doi.org/10.1093/annweh/wxad077

16. Quinn T.D., Lane A., Pettee Gabriel K., Sternfeld B., Jacobs D.R. Jr., Smith P., Barone Gibbs B. Associations between occupational physical activity and left ventricular structure and function over 25 years in CARDIA. Eur. J. Prev. Cardiol. 2024; 31(4): 425–433. https://doi.org/10.1093/eurjpc/zwad349

17. Koskela R.S. Cardiovascular diseases among foundry workers exposed to carbon monoxide. Scand. J. Work Environ. Health. 1994; 20(4): 286–93. https://doi.org/10.5271/sjweh.1396

18. Andersson L., Hedbrant A., Bryngelsson I.L., Vihlborg P., Särndahl E., Westberg H. Silica Exposure and Cardiovascular, Cerebrovascular, and Respiratory Morbidity in a Cohort of Male Swedish Iron Foundry Workers. Occup. Environ. Med. 2023; 65(9): 731–739. https://doi.org/10.1097/JOM.0000000000002890

19. Marstrand P., Han L., Day S.M., Olivotto I., Ashley E.A. et al. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020; 141(17): 1371–1383. https://doi.org/10.1161/CIRCULATIONAHA.119.044366

20. Lee H.J., Kim J., Chang S.A., Kim Y.J., Kim H.K., Lee S.C. Major clinical issues in hypertrophic cardiomyopathy. Korean Circ. J. 2022; 52: 563–75. https://doi.org/10.4070/kcj.2022.0159

21. Marstrand P., Han L., Day S.M. et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry. Circulation. 2020; 141: 1371–1383. https://doi.org/10.1161/CIRCULATIONAHA.119.044366

22. Abdelfattah O.M., Martinez M., Sayed A., ElRefaei M., Abushouk A.I., Hassan A., Masri A., Winters S.L., Kapadia S.R., Maron B.J., Rowin E., Maron M.S. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin. Electrophysiol. 2022; 8(11): 1417–1427. https://doi.org/10.1016/j.jacep.2022.07.012

23. O’Mahony C., Jichi F., Pavlou M. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur. Heart J. 2014; 35: 2010–2020. https://doi.org/10.1093/eurheartj/eht439

24. Ommen S.R., Ho C.Y., Asif I.M., Balaji S., Burke M.A., et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024; 149(23). https://doi.org/10.1161/CIR.0000000000001250

25. Goff Z.D., Calkins H. Sudden death related cardiomyopathies — hypertrophic cardiomyopathy. Prog. Cardiovasc. Dis. 2019; 62(3): 212–216. https://doi.org/10.1016/j.pcad.2019.04.001

26. Monda E., Limongelli. Integrated Sudden Cardiac Death Risk Prediction Model for Patients with Hypertrophic Cardiomyopathy. Circulation. 2023; 147(4): 281–283. https://doi.org/10.1161/CIRCULATIONAHA.122.063019

27. Kry`lova N.S., Kry`lov A.L., Poteshkina N.G., Balaeva M.A., Py`lev A.V. Hypertrophic cardiomyopathy: outcomes of the disease and their prediction. Klin. i e`ksperiment. xir. zhurn. im. akad. B.V. Petrovskogo. 2018; 6(3): 25–33. https://doi.org/10.24411/2308-1198-2018-13003 (in Russian).